期刊
ONCOTARGET
卷 6, 期 17, 页码 15283-15296出版社
IMPACT JOURNALS LLC
DOI: 10.18632/oncotarget.3681
关键词
CD44; breast cancer; selective targeting therapy; hyaluronan
资金
- National Natural Science Foundation of China [81071814, 81172027, 81272479, 81402419]
- Shanghai Leading Talents [2013-038]
- Shanghai Shen-Kang Hospital Development Center [SHDC22014004]
- Natural Science Foundation of Shanghai Municipality [10411950500, 12ZR1447400, 14YF1412200]
- Doctorial Innovation Foundation of Shanghai Jiaotong University School of Medicine [BXJ201238]
The cell surface glycoprotein CD44 is expressed in cancer cells and has been used as a therapeutic target in preclinical studies. However, the ubiquitous expression of CD44 in numerous cell types, including hematopoietic cells, has hindered its application in targeted therapy. Here, we demonstrated that CD44 was activated on breast cancer cells but was inactive on normal cells in vitro and in vivo. We analyzed 34 clinical primary tumor and normal breast tissues and demonstrated that CD44 was in an active state on breast cancer cells but in an inactive state on normal cells. Furthermore, based on the binding property of CD44 with its ligand hyaluronan (HA), we self-assembled HA-coated nanoparticles and studied their selective targeting efficacy. Our results indicate that HA-coated nanoparticles bearing the CD44 ligand selectively targeted cancer cells both in vitro and in vivo, killing breast cancer cells while sparing normal cells. Our study suggested that the active state of CD44 plays a crucial role in the selective targeting of breast cancer cells by avoiding nonspecific toxicity to CD44-quiescent normal cells. These findings may provide a new idea for the selective targeting of cancer cells in other human cancers.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据